Inclusion Criteria:

• Must give written informed consent (signed and dated) and any authorizations required by local laws (e.g., Protected Health Information PHI]).
• Age 18 years or older at the time of informed consent
• Relapsed or refractory solid tumors following standard therapy.
• Available formalin-fixed, paraffin-embedded (FFPE) tumor tissue from a tumor tissue biopsy or resection (most recent preferred) submitted either as a paraffin block or as unstained tissue sections on glass slides. Paraffin blocks or unstained slides from core needle biopsies known to contain representative tumor tissue are allowed when larger FFPE tissue samples are not available. (Fine needle aspirates are not acceptable tumor tissue samples for this study.)
• Measurable or non measurable disease according to modified Response Evaluation Criteria in Solid Tumors (RECIST).
• ECOG Performance Status 0 or 1.
• Life expectancy >12 weeks in the opinion of the Investigator.
• Male and female subjects of child-bearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for 9 months after their last dose of study treatment. Effective methods of contraception are double-barrier methods (condoms with spermicidal jelly or foam, and diaphragm with spermicidal jelly or foam); oral, depot, and injectable contraceptives; intrauterine devices (IUDs); NuvaRing; birth control patch (e.g., Ortho Evra patch); or surgical sterilization. Single-barrier methods and rhythm methods will no be considered effective contraception.

Exclusion Criteria:

• Screening clinical laboratory values:

  • Absolute neutrophil count (ANC) <1000/mcgL
  • Platelet count <75,000/mcgL
  • Hemoglobin <9.0 g/dL. Subjects must not have received transfusions within 4 weeks prior to screening.
  • Serum bilirubin >1.5 x upper limits of normal (ULN)
  • AST and ALT >2.5 X ULN (AST and ALT >5 x ULN for subjects with liver metastasis)
  • Serum creatinine >2.0 mg/dL
  • Albumin </= 2.5 g/dL
• History of insulin-dependent diabetes, type 2 diabetes, or hemoglobin A1c >6% at screening.
• History of myocardial infarction within 12 months prior to Day 1 or chronic heart failure.
• Known central nervous system or brain metastases.
• Other malignancies within 3 years of Day 1, except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, or basal or squamous cell skin cancer.
• Radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to Day 1.
• Any investigational therapies administered within 4 weeks prior to Day 1 or 5 half lives of the therapy (whichever is longer).
• Prior anti-IGF-1R therapy of any kind.
• Pregnant (positive pregnancy test) or lactating at screening.
• Inability to comply with study and follow-up procedures.
• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that leads to reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications.
• History of claustrophobia or any other condition that is incompatible with the requirements for CT/MRI or FDG-PET scanning.
• Clinically significant (as determined by the Investigator) electrocardiogram (ECG, 12 lead) abnormalities.